-
1 Comment
Tiziana Life Sciences PLC is currently in a long term downtrend where the price is trading 23.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Tiziana Life Sciences PLC gets an overall score of 1/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | BMG889121031 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.42 |
|---|---|
| Market Cap | 155M |
| PE Ratio | None |
| Target Price | 8.9846 |
| Dividend Yield | None |
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TLSA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026